LKB1 Is Crucial for TRAIL-Mediated Apoptosis Induction in Osteosarcoma
Total Page:16
File Type:pdf, Size:1020Kb
ANTICANCER RESEARCH 27: 761-768 (2007) LKB1 is Crucial for TRAIL-mediated Apoptosis Induction in Osteosarcoma SHINTARO TAKEDA1,2, ATSUSHI IWAI2,3, MITSUKO NAKASHIMA2, DAISUKE FUJIKURA2,3, SATOKO CHIBA2,3, HONG MEI LI3, JUN UEHARA2,3, SATOSHI KAWAGUCHI1, MITSUNORI KAYA1, SATOSHI NAGOYA1, TAKURO WADA1, JUNYING YUAN4, SYDONIA RAYTER5, ALAN ASHWORTH5, JOHN C. REED6, TOSHIHIKO YAMASHITA1, TOSHIMITSU UEDE2 and TADAAKI MIYAZAKI2,3 1Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Sapporo; 2Division of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo; 3Department of Bioresources, Hokkaido University Research Center for Zoonosis Control, Sapporo, 0010021, Japan; 4Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, 02115, U.S.A.; 5Cancer Research UK Gene Function and Regulation Group, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, U.K.; 6Burnham Institute for Medical Research, La Jolla, California, 92037, U.S.A. Abstract. Background: Despite improvements in Development of chemotherapy and surgery has resulted in chemotherapy and surgery in the treatment of osteosarcoma, the considerable improvement of survival rates of satisfactory results are still difficult to achieve. New therapeutic osteosarcoma patients (1), the current chemotherapeutic modalities need to be developed for the improvement of these agents still have a lot of problems to overcome, such as treatments. TRAIL (TNF-related apoptosis inducing ligand) is serious side-effects or resistance to multiple chemo- known as a selective apoptosis inducer in most tumor cells, but therapeutic agents in 20-30% of the patients (2). New not in normal cells. Therefore, TRAIL is a good candidate therapeutic modalities for these patients are driven by target for the treatment of tumors. However, sensitivity of necessity for the treatment. osteosarcoma cells to TRAIL-induced apoptosis is lower than TRAIL is a member of TNF (tumor necrosis factor) that of other types of tumor cells. Recently, DAP3 (death family proteins (3, 4). TRAIL, which selectively induces associated protein 3) was demonstrated to play a critical role in apoptosis in most tumor cells, but not in normal cells, is TRAIL-mediated apoptosis through activation of pro-caspase- expected to be a new therapeutic agent without significant 8. Here, we found that LKB1, a serine/threonine kinase, toxicities to normal tissues (5, 6). expressed in bone and soft tissue sarcoma cells, associated with Many experimental studies of the application of TRAIL DAP3. We also demonstrated that expression of DAP3 induced to osteosarcoma cells have been reported (7-15). However, apoptosis in osteosarcoma cells. Furthermore, expression of treatment of osteosarcoma cells with TRAIL did not lead LKB1 induced apoptosis and co-expression of LKB1 with to satisfactory results, since cell sensitivity to TRAIL- DAP3 strongly induced apoptosis in osteosarcoma cells. In induced apoptosis is different in various cells, and the addition, expression of LKB1 kinase dead mutant, LKB1 mechanisms for apoptosis induction remain unclear. (K78M), inhibited DAP3-induced apoptosis in these cells. Therefore, additional agents to sensitize osteosarcoma cells These results suggest that LKB1 is critical for TRAIL-induced to TRAIL-induced apoptosis have been proposed (7-11, 13- apoptosis induction, cooperating with DAP3 in osteosarcoma 15) but the problem of side-effects still remains. cells. It is predicted that LKB1 and DAP3 could be critical TRAIL receptors have been identified as TRAIL-R1 target molecules for the treatment of osteosarcomas. (DR4), TRAIL-R2 (DR5), TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) and osteoprotegrin (OPG). DR4 or DR5 induces apoptosis by TRAIL stimulation (16). In contrast, DcR1, DcR2 and OPG are not able to induce apoptosis, since their cytoplasmic death domains are deficient or incomplete (16, Correspondence to: Tadaaki Miyazaki, Department of Bioresources, 17, 19-21). Although the expression of DR4 or DR5 is Hokkaido University Research Center for Zoonosis Control, Sapporo, 0010021, Japan. required for TRAIL-mediated apoptosis, the expression of DcR1, DcR2 and OPG does not necessarily relate to cell Key Words: LKB1, TRAIL, apoptosis, osteosarcoma cells, DAP3. sensitivity to TRAIL-induced apoptosis (22, 23). Therefore, 0250-7005/2007 $2.00+.40 761 ANTICANCER RESEARCH 27: 761-768 (2007) the intracellular molecules located downstream of DR4 or viability assay experiments were repeated twice. Results of DR5 have been proposed to be a critical determinant of cell representative experiments are given as the mean+SD. sensitivity to apoptosis induced by TRAIL. Yeast two-hybrid screening. Human wild-type DAP3 gene was Pro-apoptotic cytoplasmic DAP3 associates with both the inserted and fused to the Gal4 DNA-binding domain in the vector intracellular death domain of TRAIL receptor and the Fas pGBKT7 (Trp) (BD Clontech, USA). After transformation into associated death domain (FADD) (23). The complex the yeast strain, AH109 with pGBKT7 (Empty vector) or pGBKT7- formation of these proteins by TRAIL receptor-stimulation DAP3, these transformants were selected on SD (Synthetic induces apoptosis through activation of pro-caspase 8 (24). Dropout) plates, in which the media lacks Trp. These selected yeast However, details of molecular mechanisms in TRAIL- or cells were transformed with a human fetal brain cDNA library DAP3-induced apoptosis are not fully understood. fused with Gal4ad in the vector pActII (Leu) (Clontech), and then selected on SD media lacking Trp and Leu. The positive clones Therefore, we screened the proteins which bind to DAP3, were selected and the confirmation of positive clones was carried using a yeast two hybrid system, in order to identify the out using ·-gal or ‚-gal assay. regulators for TRAIL-mediated apoptosis. As a result, we found that LIP1 (LKB1 interacting protein 1) associated Western blotting. Cells were harvested and the protein extracts from with DAP3. LIP1 was reported to interact with LKB1 (25). these cells were prepared as follows. The protein samples (20 Although LIP1 is not a substrate of LKB1, it was shown to Ìg/lane) were fractionated by SDS-PAGE on a 4-20% gradient anchor LKB1 to the cytoplasm (25). LKB1 was originally polyacrilamide gel (Daiichi Pure Chemicals, JAPAN). The analysed proteins were transferred to a PMDF filter with a semi- described with regard to its gene mutation causing Peutz- dry blotter. The blotted membrane filter was reacted either with Jeghers syndrome (PJS) (25-27), a rare hereditary disease, each antibody as shown in the Figure after blocking. This in which there is predisposition to develop benign and membrane was reacted with HRP-conjugated antibodies and malignant tumors of many organ systems (28, 29). LKB1 immunodetection of the proteins was performed using the ECL was demonstrated to be a tumor suppressor involved in the detection system (Amersham, Piscataway, NJ, USA). regulation of cell polarity (30-32). However, the function of 6 LKB1 in TRAIL-induced apoptosis is not clear. Therefore, Immunoprecipitation. HEK293T cells (2x10 ) in 10 cm cell culture plates were transiently transfected with 5 Ìg of each we studied the functional role of LKB1 in apoptosis expression vector plasmid (10 Ìg as a total DNA amount) induction by TRAIL stimulation. In addition, we examined together with 30 Ìl of Fugene 6 transfection reagent (Roche the function of LKB1 and DAP3 in TRAIL-mediated Diagnostic, Mannheim, Germany) and harvested 24 h later. Cells apoptosis in osteosarcoma cells. were suspended in 500 Ìl of lysis buffer containing 0.1% NP-40, 20 mM Tris-HCl at pH 7.5, 2 mM MgCl2, 1 mM EGTA, 150 mM Materials and Methods NaCl and protease inhibitors Complete Mini (Roche). Alternatively, untransfected HOS cells (5x108) were harvested Cell lines and plasmids. HOS, MNNG/HOS, MG63 (human and lysed in 1.5 ml of lysis buffer as described above. Cell osteosarcoma), HT1080, NIH3T3 (mouse fibrosarcoma) and extracts were reacted either with the indicated antibody in the HFO (primary cultured human fetal osteoblast) cells (15) were Figure for 1 h and then washed with the lysis buffer for five kindly donated by the Department of Pathology, Sapporo times. These samples were fractionated by SDS-PAGE and Medical University, Japan. HEK293T and 143B (human analyzed by Western blotting assay as described above. osteosarcoma) cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). These cells were Colony formation assay. HOS cells (5x105) in 35 mm cell culture cultured in Dulbeccos' modified Eagle's medium (DMEM) plates were transfected with 4 Ìg of each expression vector plasmid supplemented with 10% heat inactivated fetal bovine serum together with 10 Ìl of Lipofectamine 2000 transfection reagent (SIGMA-ALDRICH, JAPAN), 100 IU/ml penicillin and 100 (Invitrogen, CA, USA). After 24 h, these cells were cultured with Ìg/ml streptomycin (SIGMA) in a humidified atmosphere TRAIL (50 ng/ml) for 1 week. The number of colonies was determined after staining with 0.05% crystal violet solution. containing 5% CO2 at 37ÆC. Jurkat cells were cultured in the medium of RPMI-1640 supplemented with 10% heat inactivated fetal bovine serum Results (SIGMA), 100 IU/ml penicillin and 100 Ìg/ml streptomycin (SIGMA). Sensitivity of osteosarcoma cells to TRAIL-induced apoptosis. We first examined the effects of TRAIL stimulation for the Cell viability assay. Before seeding onto 96-well